Trials / Completed
CompletedNCT04627038
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 202 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to test the safety and efficacy of LY3556050 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3556050 | LY3556050 Given orally |
| DRUG | Placebo | Placebo Given orally |
Timeline
- Start date
- 2020-11-12
- Primary completion
- 2021-10-21
- Completion
- 2021-10-21
- First posted
- 2020-11-13
- Last updated
- 2023-11-02
- Results posted
- 2023-11-02
Locations
40 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04627038. Inclusion in this directory is not an endorsement.